Exclusive: After four decades, one researcher's radical HIV cure finally gets its shot

Exclusive: After four decades, one researcher's radical HIV cure finally gets its shot

Source: 
Endpoints
snippet: 

In November, Khalili gave the first evidence the approach could work in monkeys. Investors are now getting on board. Excision BioTherapeutics, the company founded around Khalili’s work, announced today a $50 million Series A to push the therapy into the clinic. If it works as intended, it could provide a long-sought single-shot cure for a virus that now infects 38 million people worldwide and set the stage for a similar approach for other chronic viruses, such as herpes and hepatitis B.